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The nature and significance ofthe distribu-
tion of mutations by base pair in the p53
gene have been the subject of investigation
in recent years because ofthe importance of
this gene in control of the cell cycle, DNA
repair and synthesis, cell differentiation,
and cell death (1-9). Mutations in the p53
gene have been found in many types ofcan-
cer and may be the most common mutation
observed in human cancers. In lung cancer,
p53 mutations have been found in 56% of
tissue samples, and in colorectal, esoph-
ageal, ovarian, pancreatic, and skin cancers,
prevalences of44-50% have been reported
(4). Mutations occur at many base pairs
throughout the gene, with higher frequen-
cies reported in exons 5-8 than at other
exons and high frequencies occurring at
specific codons (4,10-12). The diversity in
p53 mutations has suggested the possibility
of correlating exposures with specific p53
mutations, for example, vinyl chloride and
mutations at A:T base pairs in angiosarco-
mas, ultraviolet radiation and CC->TT
changes in skin cancer, aflatoxins and
G-+T mutations in liver cancer, or G:C to
A:T transitions associated with mustard gas
exposure in lung cancer patients (13-19).
Such epidemiologic correlations may be
supported by laboratory studies showing
specific mutations associated with specific
mutagens. For example, n-ethyl-n-
nitrosourea, an alkylating agent associated
with carcinogenesis in the gut and other
tissues, induces G-÷A transitions at codon
248 in human fibroblasts (20).
These observations suggest that in can-
cer cells derived from tumors in different
organs, p53 mutational spectra can be seen
as the fingerprints of the carcinogens that
caused the cancer (10,11,19,21-23). The
hypothesis that environmental carcinogens
correlate strongly with p53 mutational
spectra is the basis for suggestions that cer-
tain p53 mutations can be interpreted as
markers of exposure. Some examples of
these suggestions are 1) that the presence
ofp53 mutations in esophageal carcinoma
patients with and without human papillo-
ma virus involvement is evidence of the
role of environmental carcinogens in
esophageal carcinogenesis (24); 2) that
varying frequencies of microdeletions,
transitions, and transversions in different
breast cancer populations are compatible
with the role of different environmental
carcinogens contributing to breast cancer
carcinogenesis in different populations
(25); 3) that differences in proportions of
transversions in Japanese and American
prostate cancer patients suggests variation
in etiologic factors between the two popu-
lations (26); and 4) that observations of
the presence of G-+T changes in breast
cancer and those observed in lung cancer
(which the authors maintain are probably
caused by exogenous mutagenic chemicals)
suggest that these breast cancers were simi-
larly caused byexogenous chemicals (23).
Researchers have characterized muta-
tional variation primarily by summarizing
aggregate base pair changes throughout the
gene and presenting the data in pie charts,
histograms, or tables. These analyses indi-
cate variation in base pair changes by can-
cer: for example, differences in the propor-
tions ofA:T to C:G changes in cancers of
the skin, nasopharynx, oral cavity, and
pharynx/larynx, or differences in mutation
type (deletion, base pair substitution, splice
site, etc.) (4,21,2). Other studies have ana-
lyzed DNA change by location; these have
reported variations in hot spots (frequent
codon sites) in bladder, prostate, breast, and
other cancers (28-30). However, most of
the analyses have used individual data sets,
limited by small sample sizes that do not
permit statistical tests. The availability of
the pooled database compiled by the
European Molecular Biology Library has
allowed analyses of larger sample sizes, but
these primarily have been summaries of
base pair changes by cancer (mutational
spectra) (4,31,32).
To fully evaluate the assumption that
p53 mutational spectra reflect specific envi-
ronmental carcinogens, it is necessary to
fully describe and characterize variation in
p53 mutational spectra; the second step is
to correlate variation in p53 mutational
spectra with specific exposures. In this
paper, we extend the evaluation ofp53
mutational variation by analyzing an inter-
nationally available database ofp53 muta-
tions. We expand on previous analyses by
characterizing differences in frequent codon
sites in five cancers-breast, colorectal,
liver, lung, and ovarian-and by examining
differences by cancer in base pair changes at
six codon sites that have been identified in
the literature as p53 mutation hot spots.
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We also analyzed the predicted amino acid
change at codon sites by cancer and tested
for statistical significance by comparing rel-
ative frequencies. Because the database did
not contain information on exposures, we
were not able to correlate mutational varia-
tionwith exposures.
Methods
The European Molecular Biology Library
has compiled reports from individual stud-
ies to produce an aggregated database of
p53 mutations (31-33). The version used
in these analyses contained data describing
4,123 mutations and became available
over the Internet on 29 September 1995
(http://sunsite.unc.edu/dnam/mainpage.html).
For each mutation reported, the database
described the cancer diagnosis and type, the
base pair change, the type ofmutation (base
pair substitution, frameshift, deletion, inser-
tion, splicing mutation, complex mutation),
base pair position, codon position, wild type
codon, codon produced by mutation, wild
type amino acid, amino acid produced by
mutation, and references. The database
included reports from 443 articles published
from 1989 to 1995. Sixty-three ofthe arti-
cles contained only one report of a p53
mutation, and 296 of the articles reported
fewer than 10 mutations. Only 12 articles
reported more than 40 mutations.
The data were derived both from stud-
ies that analyzed specific exons (5-8 only),
as well as from studies that sequenced the
entire gene. Thus, the database may over-
represent mutations in exons 5-8, but
information about other exons sequenced
was not available in the database. When
the same mutations were reported in more
than one journal article, only one report
was entered in the database, but methods
for identifying duplicate reports were not
explicitly stated. Although the database
contains information regarding the type of
cancer, diagnosis and terminology were
adopted as used by the authors ofthe origi-
nal journal articles. Thus, "esophageal" and
"oesophageal" were entered as two different
cancers in the database, an indication that
terminology in journal articles was not
standardized when entering data. Despite
its limitations, the database offered a
unique opportunity to analyze adequate
sample sizes of reports ofp53 mutations
and to explore new approaches to analyzing
such databases.
Frequency counts by type of cancer,
codon site, and amino acid change were
obtained using the SAS 6.10 statistical
package (SAS, Cary, NC). We identified
the five most frequent codon sites in each
cancer to consider variation in hot spots by
type of cancer. To compare variation in
mutations at codon sites, we chose six
codon sites that have been noted as hot
spots in the literature and analyzed muta-
tions in the five cancers (breast, colorectal,
liver, lung, and ovarian) with the largest
sample sizes. Three-dimensional his-
tograms ofbase pair changes by cancer and
amino acid changes by cancer at specific
codons revealed distinct nonrandom pat-
terns that varied by cancer and by codon.
The associations between amino acid
changes and cancer type were then assessed
using prevalence ratios, an epidemiologic
measure ofeffect that compares the preva-
lence (the proportion of the group with a
characteristic) in one group to the preva-
lence ofthe same characteristic in a second
group (34). A prevalence ratio greater than
1 indicates that the event is more frequent
in the first group than in the second group;
a prevalence ratio of 3, for example, indi-
cates a prevalence three times greater in the
first group than in the second group. The
95% confidence interval (CI) for each
prevalence ratio was calculated: a CI that
overlaps 1 means that the estimate of the
prevalence ratio may include 1 (suggesting
no difference between the two groups).
p-Values were calculated using Fisher's
exact chi-square.
Results
Mutation hotspots by cancer. The five can-
cers in the database with the largest sample
sizes were breast (418), colorectal (398),
liver (341), non-small cell lung (313), and
ovarian (251), for a total of 1,721 reports
ofp53 mutations. The five cancers varied
considerably in the distribution of muta-
tions over sites (Table 1). The five most
frequent sites for p53 mutations differed.
In breast cancer, they were (in order) 273,
175, 248, 245, and 249. For liver cancer,
the five most frequent sites were codons
249, 273, 166, 157, and 159. The cancers
also varied in the proportion of mutations
occurring at these codon sites. While
codon 249 was a frequent site in both
breast and liver cancers, only 2.2% ofp53
mutations in breast cancer occurred at
codon 249, compared to 36.4% of the
mutations in liver cancer. Colorectal and
Table 1. The five most frequent codon sites (hot spots) for p53mutations in breast, colorectal, liver, lung,
and ovarian cancers and the percentages ofp53mutations occurring atthese sites for each cancer
Codon Breast Colorectal Liver Lung Ovarian
(hotspot) (n= 418) (n=398) (n=341) (n=313) (n=251)
Mostfrequent %) 273 248 249 273 273
(6.7%) (13.8%) (36.4%) (8.9%) (11.2%)
Second mostfrequent(%) 175 175 273 248 248
(6.0%) (13.6%) (4.1%) (4.5%) (5.6%)
Third mostfrequent(%) 248 273 166 179 282
(6.0%) (9.5%) (3.5%) (4.2%) (5.2%)
Fourth mostfrequent(%) 245 245 157 245 245
(3.1%) (7.0%) (1.8%) (4.2%) (4.8%)
Fifth mostfrequent (%) 249 282 159 157 175
(2.2%) (5.0%) (1.8%) (3.5%) (4.0%)
Cumulative percentage of 24.0% 48.9% 47.6% 25.3% 30.8%
five mostfrequent codon
sites out oftotal gene
Table2. Mostfrequent base pair change at codons in five cancers
Codon Breast Colorectal Liver Lung Ovarian
(hotspot) (n =418) (n= 398) (n=341) (n=313) (n= 251)
Mostfrequent 273 248 249 273 273
G6-A C-4T G-+T G-*T GA
(19/28) (31/55) (118/124) (11/28) (14/28)
Second mostfrequent 175 175 273 248 248
G-A G-A C-iT G-T C-T
(22/25) (49/54) (9/14) (5/14) (7/14)
Third mostfrequent 248 273 166 179 282
G-A G-A T-AA C-i->T
(16/25) (21/38) (12/12) (8/13) (10/13)
Fourth mostfrequent 245 245 157 245 245
G-A G--A G-+T G-T G-4A
(8/13) (23/28) (3/6) (7/13) (9/12)
Fifth mostfrequent 249 282 159 157 175
G-iT C-T G->C G-4T G-+A
(4/9) (20/20) (5/6) (10/11) (10/10)
Mostfrequent base pair G->A G-*A G-4T G-*T G-+A
change reported for entire gene (28.0%; (37.2%; (42.5%; (30.7%; (30.3%;
117/418) 148/398) 145/341) 96/313) 76/251)
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ovarian cancers shared the same five hot
spots, but the relative frequencies differed.
In colorectal cancer, 13.8% of the muta-
tions occurred at codon 248 (which was
the most frequent site), but in ovarian can-
cer, only 5.6% of the mutations occurred
at that codon (the second most frequent
site). Lung cancer shared two hot spots
with breast, colorectal, and ovarian cancers
(codons 273 and 248). Overall, 10 differ-
ent codons were identified as hot spots in
one or more ofthe five cancers.
Table 2 shows the most frequent base
pair change reported at the five most fre-
quent sites for each cancer and the most
frequent base pair changes reported
throughout the gene for each cancer. In
breast, colorectal, and ovarian cancers,
G->A changes were reported in
28.0-37.2% of all p53 mutations, and
G-4A mutations were frequently reported
at hot spots. C-*T changes were frequent
at two hot spots in colorectal cancer and in
ovarian cancer, and G-*T changes were
frequent in the fifth hot spot in breast can-
cer. In both liver and lung cancers, G-T
base pair changes predominated (42.5%
and 30.7% of all reported mutations,
respectively), but the two cancers shared
only two hot spots, codons 157 and 273.
At the five hot spots in liver cancer, the
most frequent base pair changes were
G-4T, C-*T, T->A, G->T, and G-*C
(from most frequent site to fifth most fre-
quent site), but in lung cancer, G->T base
pair changes predominated at four of the
five hot spots.
Thus, the distribution of base pair
changes over hot spots varied by cancer.
While G-4A base pair changes were the
most frequently reported changes in all p53
mutations in breast, colorectal, and ovarian
cancers, G-+Achanges predominated at four
hot spots in breast cancer and G->A and
C-4Twere frequent at hotspots in both col-
orectal and ovarian cancers. Similarly, while
G-+T changes were the most frequently
reported changes in allp53mutations in liver
and lung cancers, G->T changes predomi-
nated at four hot spots in lung cancer, but
four different base pair changes predominat-
ed at hotspots in liver cancer.
Base pair and amino acid changes by
cancerfor six codons. The next analysis
examined the diversity of mutations at six
p53 mutation hot spots identified in the
literature, codons 248, 245, 249, 175, 273,
and 282, by type ofcancer, to see ifspecific
or distinctive mutations were associated
with the cancers. Because different cancers
do not appear to share similar hot spots, as
shown in the previous analysis, we could
not compare the types of mutations at the
five most frequent mutation sites in each
cancer. Instead we compared base pair and
amino acid changes by cancer at six hot
spots identified in the literature (4). In
addition to describing the most frequent
base pair changes at each codon by cancer,
we compared relative frequencies by codon
and by cancer to find mutations associated
with each ofthe five cancers.
Table 3 summarizes the number of
reported p53 mutations at codons 248,
245, 249, 175, 283, and 282 and their rel-
ative frequencies by type ofcancer and spe-
cific amino acid changes that resulted.
Thus, there were nine reports of arginine
(Arg) to tryptophan (Trp) changes at
codon 248 among 418 reports of all p53
mutations in breast cancer, for a relative
frequency of 2.15%, and 31 such muta-
tions out of398 p53 mutations reported in
colorectal cancer, for a relative frequency of
7.78%. As noted previously in Table 1, few
codons are the sites for more than 10% of
the mutations reported for a type ofcancer.
For all five cancers, the most frequent site
accounted for 6.7-36.4% ofall p53 muta-
tions, and the fifth most frequent site
accounted for only 1.8-5.0% of reported
p53 mutations. Analyzing individual types
of mutations at a codon site describes
events that account for even lower percent-
ages ofthe total. For example, while codon
273 was the most frequent site ofp53
mutations in breast cancer (6.7%), the Arg
to histidine (His) changes at codon 273
comprised 19, or 4.54%, ofall breast can-
cer p53 mutations, the Arg to cysteine
(Cys) changes accounted for 6, or 1.43%,
and the Arg to leucine (Leu) change
accounted for 1, or 0.23%.
To estimate the strength of association
between specific mutations and cancers and
to test the statistical significance ofthe varia-
tion, the relative frequency of particular
amino acid changes at a given codon in one
type ofcancer was compared to the relative
frequency of the same change in the other
cancers (Table 4). For example, Arg to Trp
changes at codon 248 accounted for 7.79%
ofall thep53mutations reported in colorec-
tal cancer, but only 1.59% ofthep53muta-
Table 4. Calculation of prevalence ratios
All other
mutations
Codon 248, atany
Cancer ArgtoTrp codon Total
Colorectal cancer 31 367 398
(7.79%)
Breast, liver, lung, 21 1,302 1,323
and ovarian cancers (1.59%)
Prevalence ratio (colorectal vs. breast, liver, lung,
and ovarian) = 4.9;95% Cl =2.9-8.4; p<0.001.
Table3. Number and percentages ofspecific base pair and amino acid changes out ofthe total p53muta-
tions reported for each offive cancers
Amino acid and
Codon base pair change
248 Arg toTrp
(CGG) C-*T
Arg to Gln
G-iA
Arg to Leu
G-+T
245 Glyto Ser
(GGC) G-*A
Glyto Asp
G-+A
Glyto Cys
G->T
249 Arg to Ser
(AGG) G-T
175 Arg to His
(CGC) G-*A
273 Arg to His
(CGT) G-4A
Arg to Cys
C->T
Arg to Leu
G-+T
282 Arg to Trp
(CGG) C-T
Total mutations
analyzed above
Total mutations
reported
Breast
9
(2.15%)
16
(3.83%)
0
4
(0.95%)
4
(0.95%)
1
(0.23%)
5
(1.19%)
22
(5.26%)
19
(4.55%)
6
(1.43%)
l
(0.23%)
3
(0.71%)
90
(21.53%)
418
Colorectal
31
(7.78%)
23
(5.78%)
(0.25%)
14
(3.52%)
9
(2.26%)
2
(0.50%)
2
(0.50%)
49
(12.31%)
21
(5.28%)
17
(4.27%)
0
20
(5.02%)
189
(47.49%)
398
Liver
(0.29%)
4
(1.17%)
0
0
0
3
(0.87%)
114
(33.43%)
2
(0.58%)
(0.29%)
9
(2.63%)
3
(0.87%)
2
(0.58%)
139
(40.76%)
339
Lung
4
(1.27%)
3
(0.95%)
6
(1.92%)
2
(0.63%)
3
(0.95%)
5
(1.60%)
8
(2.55%)
2
(0.63%)
5
(1.59%)
3
(0.95%)
11
(3.51%)
8
(2.55%)
60
(19.17%)
313
Ovarian
7
(2.79%)
5
(1.99%)
0
8
(3.19%)
l
(0.40%)
0
2
(0.80%)
10
(3.98%)
14
(5.5%)
13
(5.18%)
0
10
(3.98%)
70
(27.89%)
251
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Figure 1. Frequency of changes at codon 248 for breast, colorectal, liver, lung, and ovarian cancers. (A) Frequency of base pair changes (CGG); GG->TT indicates
thattwo base pair changes were observed in the same report. (B) Frequency of amino acid changes (Arg).
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Figure 2. Frequency of changes at codon 245 for breast, colorectal, liver, lung, and ovarian cancers. (A) Frequency of base pair changes (GGC); GG-*CA and
GC-TT indicate thattwo base pairchanges were observed in the same report. (B) Frequency ofamino acid changes(Gly).
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Figure 3. Frequency of changes at codon 249 for breast, colorectal, liver, lung, and ovarian cancers. (A) Frequency of base pair changes (AGG). (B) Frequency of
amino acid changes (Arg).
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Figure 4. Frequency of changes at codon 175 for breast, colorectal, liver, lung, and ovarian cancers. (A) Frequency of base pair changes (CGC). (B) Frequency of
amino acid changes (Arg).
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Figure 5. Frequency of changes at codon 273 for breast, colorectal, liver, lung, and ovarian cancers. (A) Frequency of base pair changes (CGT); CG-AA indicates
thattwo base pair changes were observed in the same report. (B) Frequency of amino acid changes (Arg).
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Figure 6. Frequency of changes at codon 282 for breast, colorectal, liver, lung, and ovarian cancers. (A) Frequency of base pair changes (CGG). (B) Frequency of
amino acid changes (Arg).
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tions reported in breast, liver, lung, and
ovarian cancers. Thus, itwas 4.9 times more
likely to be observed in colorectal cancer
than in the other four cancers. The 95% CI
of this ratio was 2.9-8.4 with a p-value
<0.001, indicating that the difference is
greater than that expected by chance alone.
We did not develop a statistical method for
determining appropriate comparisons, but
relied on histograms to suggest comparisons.
Three-dimensional histograms of muta-
tion frequency by base pair change and can-
cer or amino acid change and cancer were
useful in visualizing the distinct patterns at
each of the codons analyzed (Figs. 1-6).
Figure 4A and B, for example, show the fre-
quency distributions of mutations at codon
175 by type of base pair change and by
amino acid change. The histograms indicate
that G->A (Arg to His) changes may be
associated with ovarian, colorectal, and
breast cancers, but notwithliverorlungcan-
cers. Figure 5A and B show the more com-
plex pattern ofmutations occurring at codon
273. Six different basepairchanges occurred,
resulting in six different amino acid changes;
however, most ofthe amino acid changes are
to His or Cys except for lung cancer, where
Arg tO Leu (G->T) changes appeared more
frequently. In colorectal cancer, Arg to His
and Arg to Cys (G-4A and C-*T) were the
onlychanges reported atthis codon.
The three-dimensional histograms were
used to suggest comparisons for statistical
analysis, andTable 5 describes theprevalence
ratios for specific amino acid changes at
codons 245, 248, 249, 175, 273, and 282.
For example, atcodon 248, theprevalence of
Arg to Trp changes in colorectal cancer was
compared to the prevalence of those events
in the otherfour cancers. At the same codon,
the prevalence ofArg to glutamine (Gln)
Table 5. Prevalence ratios, 95% confidence intervals, and p-values for associations between amino acid
changes and cancer at six codons
Amino acid and
Codon base pair change Breast Colorectal Liver Lung Ovarian
248 Arg to Trp 4.9a
(CGG) C-T (2.9-8.4)
p<O.001
Arg to Gln 2.9b 44b
G-oA (1.4-6.0) (2.2-8.7)
p<0.006 p<O.OO1
Arg to Leu - 27.OC
G-T (3.3-223.4)
p<O.OO1
245 Glyto Ser 63d 5.7d
(GGC) G->A (2.4-16.2) (2.0-16.3)
p<O.OO1 p<0.002
Glyto Asp 3.7a
G-4A (1.5-9.6)
p<O.007
Glyto Cys 3.7C
G-J (1.15-12.2)
p<O.05
249 Arg to Ser - - 27.6e-
(AGG) G-JT(G-C) (16.8-45.3)
p<0.001
175 Arg to His 3.4b 8 -b
(CGC) G-+A (1.8-6.6) (4.4-14.2)
p<0.001 p<0.001
273 Arg to His 5.0f 5.8f - 6.1f
(CGT) G-*A (2.0-12.3) (2.3-14.1) (2.4-15.6)
p<0.001 p<0.001 p<0.001
Arg to Cys 2.5d 3.1d
C-+T (1.3-4.9) (1.5-6.2)
p<0.007 p<0.003
Arg to Leu 12.4c
G-+T (4.0-38.6)
p<0.001
282 Arg to Trp 7.69 3.99 6.0-
(CGT) C-T (2.9-20.2) (1.3-11.8) (2.1-17.5)
p<0.001 p<0.03 p<0.001
aColorectal cancer compared to the otherfour cancers.
bBreast or colorectal cancer compared tothe otherthree cancers.
cLung cancer compared to the otherfour cancers.
dColorectal or ovarian cancer compared to the otherthree cancers.
eLiver cancer compared tothe otherfour cancers.
fBreast, colorectal, or ovarian cancers compared to liver and lung cancers.
gColorectal, lung, or ovarian cancers compared to breast and liver cancers.
changes in breast cancer was compared to its
prevalence inliver, lung, and ovarian cancers;
the prevalence of the same changes in col-
orectal cancer was also compared to the
prevalence inliver, lung, and ovarian cancers.
At codon 248, Arg to Trp (C-iT) changes
were associated with colorectal cancer only
(compared to the other four cancers), but
Arg to Gln (G-A) changes were associated
with both breast and colorectal cancers com-
pared to the other three cancers. Arg to Leu
(G-*T) changes were associated with lung
cancer only. At codon 245, glycine (Gly) to
serine (Ser) (G-A) changes were associated
with colorectal and ovarian cancers, Gly to
aspartic acid (Asp) (G-*A) was associated
with colorectal cancer only, and Gly to Cys
(G--T) was associated with lung cancer
only. At codon 249, Arg to Ser (G->T and
G-*C) changeswerestronglyassociatedwith
liver cancer only. At codon 175, Arg to His
(G-A) changes were associated with breast
and liver cancers, but not with colorectal,
lung, or ovarian cancers. At codon 273, Arg
to His (G-A) changes were associated with
breast, colorectal, and ovarian cancers, Argto
Cys (C-*T) changes were associated with
colorectal and ovarian cancers, and Arg to
Leu (G-4T) changes were associated with
lung cancer only. At codon 282, Arg to Trp
(C-*T) changes were associated with col-
orectal, lung, and ovarian cancers, but not
with breast or liver cancers. All ofthe above
associations were statisticalysignificant.
Discussion
The five most frequent sites ofp53 muta-
tions were different in breast, colorectal,
lung, liver, and ovarian cancers. This is con-
sistent with previous reports in the litera-
ture that hot spots and mutational spectra
vary by cancer (1,4,12,29,32). The varia-
tion in hot spots is not explained by the
predominance ofspecific base pair changes
in each cancer. Thus, while G->T base pair
changes were the most frequent changes in
both liver and lung cancers, the two cancers
shared only two hot spots. The great major-
ity (118/145) ofG-iTchanges in liver can-
cer occurred at codon 249, its number one
hot spot, but codon 249 was not a hot spot
in lung cancer. Even at a shared hot spot,
codon 273, different patterns of base pair
changes were observed, with C-*T more
frequent in liver cancer and G-*T more
frequent in lung cancer. In some ofthe can-
cers, the percentages ofmutations were low
even at the most frequent sites, suggesting
the need to further define the term hot spot
and also suggesting that some cancers may
nothave true hot spots forp53mutations.
In ouranalyses we compared relative fre-
quencies as well as absolute numbers of
events. These statistical methods identified
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associations even when absolute frequencies
were low, as in the example ofovarian can-
cer andp53 mutations at codon 282. Only
13 mutations were reported at codon 282 in
patients with ovarian cancer, but 10 ofthese
were C-*T mutations resulting in Arg to
Trp changes in the codon. The prevalence
oftheseArg to Trp changes in the sample of
mutations reported in ovarian cancer was
3.98%, six times the prevalence observed in
breast and liver cancers. In this example, the
small number of mutations at the codon
consisted primarily of one particular amino
acidchange and the dustering ofone type of
change was not explained by chance varia-
tion. At some sites, more than one type of
base pair or amino acid change was associat-
ed with some cancers but not with others.
Both C->T and G->A base pair changes
were associated with colorectal cancer at
codons 248 and 273; only G->A changes
were associated with breast cancer at these
codons; and both C-iT and G-*A changes
were associated with ovarian cancer only at
codon 273. It is possible that the colorectal
and ovarian cancer tissue samples used in
studies in the database consisted ofdifferent
groups: one exposed to carcinogens causing
G-*A changes and one exposed to carcino-
gens causing C->T changes, but the data do
not permit such an analysis. The unique dis-
tribution of G->A and C-*T changes at
codons 248 and 273 in breast and ovarian
cancers is not explained by the fact that
these are CpG sites.
These analyses point out the value of
describing the distribution of mutations
throughout the gene instead of reporting
aggregate summaries of the total base pair
changes. Additionally, information on
resultant amino acid changes provides fur-
ther information. Such analysis allowed us
to consider the diversity of mutations at
specific codons by type of cancer and by
their possible effects on the gene product.
Changes to Cys at codon 245, His at 175,
and His or Cys at 273 suggest that some
mutations may have a greater effect than
others on the structure and function ofthe
p53gene product.
Two factors have been postulated to
explain variation in the distribution ofp53
mutations by cancer (4,29). The first is the
role of different exposures and their effect
on thep53 gene. Ifdifferent mutagens have
distinct effects on p53 mutational spectra
and are associated with cancers in different
tissues, one would expect to observe muta-
tion distributions thatvarybycancer type. A
second source of variation may be clonal
selection factors that couldmodifythe origi-
nally induced mutational spectra to those
that are eventually observed in tumor cells.
Ifclonal selection factors varybyorgan, then
cancers in different organs would show dif-
ferent distributions ofp53 mutations and
such variation would also correlate with the
different carcinogens associated with differ-
ent cancers.
If the carcinogens are the main deter-
minants ofp53 mutation distributions,
similar patterns should be observed in
patients with similar carcinogen exposures,
even if their cancer occurs in different
organs. Thus, lung cancer and bladder can-
cer in smokers would be expected to show
similar p53 mutation distributions. If
organ-specific clonal selection forces are the
main determinants ofp53 mutation distri-
butions, variation by cancer type should be
observed regardless of exposure etiology.
To test these hypotheses, the association
between thep53 mutation distribution and
the cancer type must be evaluated with
adequate patient sample sizes, appropriate
statistical tests, and confirmed exposure
histories. For example, estimation of the
independent effects of radon and cigarette
smoking on p53 mutations would require
samples from tumors collected from four
groups: radon-exposed patients who were
nonsmokers, nonsmokers without radon
exposure, patients exposed to both, and
patients exposed to neither smoking nor
radon. As Esteve et al. (21) have pointed
out, access to tissue samples with detailed
exposure histories presents its own set of
methodologic issues, usually relying on
paraffin-embedded tissue that may be sub-
optimal for genetic analysis.
Lackingvalidated exposure histories, we
cannot test these hypotheses with the data-
base we analyzed. It is, of course, possible
that both exposure and clonal selection
shape the mutational spectra that are even-
tually observed, as suggested by the pat-
terns ofmutations occurring at codon 273.
Codon 273 is the only codon that is a hot
spot for all five cancers, and G-*A and
C->T base pair changes at codon 273 fre-
quently result in amino acid changes to
Cys or His in breast, colorectal, and ovari-
an cancers, both ofwhich might be expect-
ed to alter the conformation and function
ofthe p53 protein. Both types ofbase pair
changes are associated with colorectal and
ovarian cancers, but G-*A (Arg to His)
changes are associated with breast cancer
only. In lung cancer, mutations at codon
273 are most frequently Arg to Leu
changes resulting from G->T base pair
changes. The pattern observed in lung can-
cer is consistent with suggestions that
G-*T transversions are more common in
smokers than in nonsmokers and are fre-
quently observed in small-cell lung cancer
and that benzo[a]pyrene diol epoxide
(BPDE) adducts form at codon 273(4,35).
Inferences drawn from these data are
limited by the data quality and by the lack
of crucial information, particularly com-
plete sequencing ofthep53gene and ascer-
tainment of exposure histories. In breast
cancer, 22% ofp53 mutations have been
reported to lie outside exons 5-8, although
all missense mutations were reported with-
in exons 5-8; thus, analyses relying on
studies with differences in the exons
sequenced may report different results (36).
Inferences are also limited by the sample, a
nonrandom, nonrepresentative selection of
patients that may not truly reflect the dis-
tribution ofp53 mutations in these can-
cers. The database is also limited by the
absence ofdata describing age, gender, eth-
nicity, exposure history, severity of illness,
co-morbidity, medications, and other char-
acteristics ofthe patients. It was not possi-
ble to assess whether this was a representa-
tive sample of patients or which of these
patient characteristics could have affected
the overall distribution of mutations
observed in the database.
The variation inp53mutation distribu-
tions is more complex than has been previ-
ously described. The distributions vary by
cancer in the sites (hot spots) of frequent
mutations, the relative frequencies ofmuta-
tions at hot spots, and specific base pair
and amino acid changes at individual
codons. Specific amino acid changes are
associated with different cancers, and these
patterns were statistically significant.
Variations in organ-specific exposures and
variations in organ-specific clonal selection
factors mayexplain these associations, but a
definitive assessment ofthe contribution of
these forces to variation, as well as descrip-
tion of other correlates ofp53 mutation
distributions, awaits further epidemiologic
and laboratory research.
A great deal of attention has been
focused on the relationship between muta-
gens and observed p53 mutations without
adequately considering the effects ofclonal
selection and without adequately consider-
ing the combined effects ofdifferent muta-
gens on p53 mutational distributions.
Thus, while mutagens may cause distinct
p53mutations, it is not clear how such pat-
terns might be shaped by exposure to mul-
tiple mutagens or by clonal selection forces.
It is also not clear whether the correlation
between mutagen and p53 mutational dis-
tributions will be consistently observed in
molecular epidemiologic studies after mod-
ification by clonal selection. There is much
work to be done in characterizing the
extent and nature ofvariation inp53 muta-
tion distributions by cancer. Before
describing the extent of such variation, it
seems premature to conclude that the vari-
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ation is a marker for or evidence of the
exposure that caused the cancer and that
no other factors influence the distribution
ofp53mutations.
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